On May 27, 2025, Lyell Immunopharma, Inc. announced a reverse stock split at a ratio of 1-for-20, effective May 30, 2025, which will reduce the outstanding shares from about 296 million to approximately 14.8 million. This change was approved by stockholders on May 15, 2025, and it will be effective for trading on June 2, 2025.